Bone Biologics Corp Stock Buy Hold or Sell Recommendation
| BBLG Stock | USD 1.25 0.02 1.63% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Bone Biologics Corp is 'Strong Sell'. Macroaxis provides Bone Biologics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding BBLG positions.
Check out Bone Biologics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Bone and provide practical buy, sell, or hold advice based on investors' constraints. Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Bone |
Execute Bone Biologics Buy or Sell Advice
The Bone recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Bone Biologics Corp. Macroaxis does not own or have any residual interests in Bone Biologics Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Bone Biologics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Bone Biologics Trading Alerts and Improvement Suggestions
| Bone Biologics Corp is way too risky over 90 days horizon | |
| Bone Biologics Corp may become a speculative penny stock | |
| Bone Biologics Corp appears to be risky and price may revert if volatility continues | |
| Bone Biologics Corp has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (8.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bone Biologics Corp currently holds about 5.45 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Bone Biologics Corp has a frail financial position based on the latest SEC disclosures |
Bone Biologics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bone analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bone analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Bone Biologics Returns Distribution Density
The distribution of Bone Biologics' historical returns is an attempt to chart the uncertainty of Bone Biologics' future price movements. The chart of the probability distribution of Bone Biologics daily returns describes the distribution of returns around its average expected value. We use Bone Biologics Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Bone Biologics returns is essential to provide solid investment advice for Bone Biologics.
| Mean Return | 0.88 | Value At Risk | -17.14 | Potential Upside | 18.13 | Standard Deviation | 19.50 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Bone Biologics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Bone Stock Institutional Investors
| Shares | Ubs Group Ag | 2024-06-30 | 33.7 K | Hrt Financial Llc | 2024-06-30 | 17.5 K | Tower Research Capital Llc | 2024-06-30 | 5.8 K | Mcmahon Financial Advisors, Llc | 2024-09-30 | 403 | Bank Of America Corp | 2024-06-30 | 9.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Bone Biologics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (931.2K) | (24.1K) | 6.7M | 862.9K | (4.5M) | (4.3M) | |
| Free Cash Flow | (3.3M) | (426.9K) | (1.2M) | (3.6M) | (9.6M) | (9.1M) | |
| Other Non Cash Items | 257.8K | 938.1K | 495.6K | (2.2M) | (892.7K) | (848.1K) | |
| Net Income | (3.4M) | (1.8M) | (1.6M) | (1.5M) | (8.9M) | (8.5M) | |
| End Period Cash Flow | 24.1K | 2.5K | 6.7M | 7.5M | 3.0M | 1.8M | |
| Change To Netincome | (182.1K) | 29.8K | 60K | 702.6K | 632.3K | 600.7K |
Bone Biologics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Bone Biologics or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Bone Biologics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Bone stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.70 | |
β | Beta against Dow Jones | 1.71 | |
σ | Overall volatility | 19.76 | |
Ir | Information ratio | 0.04 |
Bone Biologics Volatility Alert
Bone Biologics Corp is showing large volatility of returns over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Bone Biologics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Bone Biologics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Bone Biologics Fundamentals Vs Peers
Comparing Bone Biologics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Bone Biologics' direct or indirect competition across all of the common fundamentals between Bone Biologics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Bone Biologics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Bone Biologics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Bone Biologics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Bone Biologics to competition |
| Fundamentals | Bone Biologics | Peer Average |
| Return On Equity | -1.19 | -0.31 |
| Return On Asset | -0.57 | -0.14 |
| Current Valuation | (536.28 K) | 16.62 B |
| Shares Outstanding | 2.46 M | 571.82 M |
| Shares Owned By Insiders | 5.21 % | 10.09 % |
| Shares Owned By Institutions | 4.58 % | 39.21 % |
| Number Of Shares Shorted | 72.06 K | 4.71 M |
| Price To Earning | (15.45) X | 28.72 X |
| Price To Book | 0.80 X | 9.51 X |
| EBITDA | 479.57 K | 3.9 B |
| Net Income | (8.95 M) | 570.98 M |
| Cash And Equivalents | 5.45 M | 2.7 B |
| Cash Per Share | 0.53 X | 5.01 X |
| Total Debt | 831.4 K | 5.32 B |
| Current Ratio | 80.11 X | 2.16 X |
| Book Value Per Share | 5.44 X | 1.93 K |
| Cash Flow From Operations | (9.56 M) | 971.22 M |
| Short Ratio | 0.18 X | 4.00 X |
| Earnings Per Share | (1.46) X | 3.12 X |
| Target Price | 16.75 | |
| Number Of Employees | 2 | 18.84 K |
| Beta | 0.74 | -0.15 |
| Market Capitalization | 3.03 M | 19.03 B |
| Total Asset | 3.74 M | 29.47 B |
| Retained Earnings | (80.91 M) | 9.33 B |
| Working Capital | 2.91 M | 1.48 B |
| Current Asset | 1.07 M | 9.34 B |
| Current Liabilities | 2.16 M | 7.9 B |
| Net Asset | 3.74 M |
Note: Acquisition by Angle Siddhesh Rajendra of 30713 shares of Bone Biologics at 1.73 subject to Rule 16b-3 [view details]
Bone Biologics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Bone . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 1784.35 | |||
| Daily Balance Of Power | 0.2857 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 1.25 | |||
| Day Typical Price | 1.25 | |||
| Price Action Indicator | 0.005 | |||
| Period Momentum Indicator | 0.02 |
About Bone Biologics Buy or Sell Advice
When is the right time to buy or sell Bone Biologics Corp? Buying financial instruments such as Bone Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Bone Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Bone Biologics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.